Related Experiment Video

Updated: Aug 2, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

TBX21 attenuates colorectal cancer progression via an ARHGAP29/RSK/GSK3β dependent manner

Xinyu Jiang1, Wenfei Du1, Chenglong Yang1

  • 1Key Laboratory of Precision Oncology in Universities of Shandong, Institute of Precision Medicine, Jining Medical University, Jining, 272067, China.

Cellular Oncology (Dordrecht, Netherlands)
|April 17, 2023
PubMed
Abstract

Insights

T-Box Transcription Factor 21 (TBX21) is decreased in colorectal cancer (CRC) and suppresses tumor progression by inhibiting proliferation and promoting apoptosis via the ARHGAP29/RSK/GSK3β pathway, offering a potential therapeutic target for CRC.

Area of Science:

  • Immunology and Cancer Biology
  • Molecular Oncology

Background:

  • T-Box Transcription Factor 21 (TBX21) is implicated in immune responses and tumor progression.
  • The specific role of TBX21 in colorectal cancer (CRC) has not been previously elucidated.

Purpose of the Study:

  • To investigate the expression and function of TBX21 in colorectal cancer.
  • To identify downstream targets and signaling pathways regulated by TBX21 in CRC.

Main Methods:

  • Immunohistochemistry (IHC) for TBX21 expression in CRC tissues.
  • In vitro and in vivo assays for cell proliferation and apoptosis.
  • RNA-sequencing (RNA-seq) to identify TBX21 target genes.
  • Human phospho-kinase array to analyze downstream signaling.

Main Results:

  • TBX21 expression is significantly reduced in CRC tissues and negatively correlates with TNM stage.
  • Ectopic TBX21 expression inhibits CRC cell proliferation and enhances apoptosis in vitro.
  • TBX21 suppresses colorectal tumor progression in vivo via the ARHGAP29/RSK/GSK3β signaling pathway.

Conclusions:

  • TBX21 acts as a tumor suppressor in colorectal cancer.
  • The findings suggest TBX21 as a potential therapeutic target for CRC treatment.
Keywords:
ARHGAP29ApoptosisColorectal cancerGSK3βProliferationRSKTBX21

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

994

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K